Transcatheter Valve Replacement for Tricuspid Regurgitation

(PATHFINDER Trial)

This trial tests two different transcatheter valve replacement systems for individuals with severe tricuspid regurgitation, a condition where the heart's tricuspid valve leaks blood backward. The goal is to evaluate the safety and effectiveness of these new treatments. Participants will receive either the Medtronic Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) System or the Edwards EVOQUE Tricuspid Valve Replacement (TTVR) System. This trial suits those who continue to experience symptoms despite optimal medical therapy and have been deemed suitable for the procedure by a specialized heart team. As an unphased trial, it offers patients the opportunity to access innovative treatments not yet widely available.

Research has shown that the Edwards EVOQUE Transcatheter Tricuspid Valve Replacement (TTVR) System has been safe in past studies. Specifically, data from over 1,000 patients revealed a low 30-day death rate of 3.1%, a stroke rate of 0.2%, and bleeding events at 7.9%. These results suggest that the EVOQUE system is generally well-tolerated.

Unfortunately, no safety data is available for the Medtronic Intrepid™ TTVR System. Since this trial is not assigned a specific phase, it lacks direct safety evidence from earlier studies.

Most treatments for tricuspid regurgitation involve open-heart surgery, which can be risky and requires a long recovery time. The Edwards EVOQUE and Medtronic Intrepid™ TTVR systems are exciting because they offer a less invasive option through transcatheter valve replacement, which means the new valve is delivered via a catheter, avoiding the need for open-heart surgery. This approach potentially reduces recovery time and the overall risk associated with the procedure. Researchers are optimistic that these systems could provide a safer and more accessible treatment for patients who are not ideal candidates for traditional surgery.

This trial will compare the Edwards EVOQUE TTVR system and the Medtronic Intrepid TTVR system for treating severe tricuspid regurgitation. Studies have shown that the Edwards EVOQUE TTVR system works well for this condition. Research involving over 1,000 patients indicates that most experienced fewer symptoms and improved heart function. Specifically, 98% of patients saw their condition improve, and many reported feeling healthier with a better quality of life. The EVOQUE system also maintains good results over time, including enhanced heart valve performance.